MorphoSys AG (MOR.DE)

21.65 -0.58 (-2.61%) At close: 05:35PM CEST

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 89927 0
https://www.morphosys.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 652

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jean-Paul Kress M.D.	Chairman of Management Board, MD & CEO	1.94M	N/A	1965
Mr. Sung H. Lee	CFO & Member of Management Board	488.7k	N/A	1970
Dr. Malte Peters M.D.	Chief R&D Officer and Member of the Management Board	1.15M	N/A	1962
Dr. Marlies Sproll	Special Adviser to the Chief Exec. Officer	N/A	N/A	1958
Mr. Klaus De Wall	Head of Accounting & Tax	N/A	N/A	N/A
Ms. Lara Smith Weber	Head of Controlling, Corp. Fin. & Corp. Devel.	N/A	N/A	N/A
Dr. Margit Urban	Head of Discovery Alliances & Technologies	N/A	N/A	N/A
Dr. Anja Pomrehn	Sr. VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Charlotte Lohmann	Sr. VP of Legal, Compliance & IP and Gen. Counsel	N/A	N/A	1970
Mr. Thomas Biegi	VP & Head of Corp. Communications	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Corporate governance

MorphoSys AG’s ISS governance QualityScore as of 1 July 2022 is 1. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.